These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 31816869)

  • 21. Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer.
    Bahrami A; Hassanian SM; ShahidSales S; Farjami Z; Hasanzadeh M; Anvari K; Aledavood A; Maftouh M; Ferns GA; Khazaei M; Avan A
    J Cell Physiol; 2018 Mar; 233(3):2058-2066. PubMed ID: 28262927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.
    Hsu HC; Thiam TK; Lu YJ; Yeh CY; Tsai WS; You JF; Hung HY; Tsai CN; Hsu A; Chen HC; Chen SJ; Yang TS
    Oncotarget; 2016 Apr; 7(16):22257-70. PubMed ID: 26989027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RAS status in Korean patients with stage III and IV colorectal cancer.
    Lee WS; Lee JN; Baek JH; Park YH
    Clin Transl Oncol; 2015 Sep; 17(9):751-6. PubMed ID: 25997687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activating
    Shirazi F; Jones RJ; Singh RK; Zou J; Kuiatse I; Berkova Z; Wang H; Lee HC; Hong S; Dick L; Chattopadhyay N; Orlowski RZ
    Proc Natl Acad Sci U S A; 2020 Aug; 117(33):20004-20014. PubMed ID: 32747568
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical and Functional Characterization of Atypical
    Loree JM; Wang Y; Syed MA; Sorokin AV; Coker O; Xiu J; Weinberg BA; Vanderwalde AM; Tesfaye A; Raymond VM; Miron B; Tarcic G; Zelichov O; Broaddus RR; Ng PKS; Jeong KJ; Tsang YH; Mills GB; Overman MJ; Grothey A; Marshall JL; Kopetz S
    Clin Cancer Res; 2021 Aug; 27(16):4587-4598. PubMed ID: 34117033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
    Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
    Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between KRAS and NRAS mutational status and clinicopathological features in 414 cases of metastatic colorectal cancer in Morocco: the largest North African case series.
    Mahdi Y; Khmou M; Souadka A; Agouri HE; Ech-Charif S; Mounjid C; Khannoussi BE
    BMC Gastroenterol; 2023 Jun; 23(1):193. PubMed ID: 37277698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.
    Xu J; Haigis KM; Firestone AJ; McNerney ME; Li Q; Davis E; Chen SC; Nakitandwe J; Downing J; Jacks T; Le Beau MM; Shannon K
    Cancer Discov; 2013 Sep; 3(9):993-1001. PubMed ID: 23733505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
    Normanno N; Rachiglio AM; Lambiase M; Martinelli E; Fenizia F; Esposito C; Roma C; Troiani T; Rizzi D; Tatangelo F; Botti G; Maiello E; Colucci G; Ciardiello F;
    Ann Oncol; 2015 Aug; 26(8):1710-4. PubMed ID: 25851630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is there any correlation among MKK4
    Dogan M; Guresci S; Acikgoz Y; Ergun Y; Kos FT; Bozdogan O; Bal O
    Expert Rev Mol Diagn; 2020 Aug; 20(8):851-859. PubMed ID: 32552144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma.
    Franczak C; Dubouis L; Gilson P; Husson M; Rouyer M; Demange J; Leroux A; Merlin JL; Harlé A
    PLoS One; 2019; 14(2):e0212801. PubMed ID: 30811471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of KRAS/NRAS, IL-4 VNTR and HPV alterations in metastases of colorectal cancer.
    Ozen F; Yegin Z; Avsar C; Zenginkinet T; Koc H; Ulasoglu C
    Bratisl Lek Listy; 2022; 123(10):758-768. PubMed ID: 35913013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.
    Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE
    Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
    Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
    BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?
    Yang L; Dong D; Fang M; Zhu Y; Zang Y; Liu Z; Zhang H; Ying J; Zhao X; Tian J
    Eur Radiol; 2018 May; 28(5):2058-2067. PubMed ID: 29335867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using tumor habitat-derived radiomic analysis during pretreatment
    Zhao H; Su Y; Wang Y; Lyu Z; Xu P; Gu W; Tian L; Fu P
    Cancer Imaging; 2024 Feb; 24(1):26. PubMed ID: 38342905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
    Modest DP; Ricard I; Heinemann V; Hegewisch-Becker S; Schmiegel W; Porschen R; Stintzing S; Graeven U; Arnold D; von Weikersthal LF; Giessen-Jung C; Stahler A; Schmoll HJ; Jung A; Kirchner T; Tannapfel A; Reinacher-Schick A
    Ann Oncol; 2016 Sep; 27(9):1746-53. PubMed ID: 27358379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
    Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
    Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Combined detection of KRAS, NRAS, BRAF and PIK3CA mutations in the plasma and tumor tissues of colorectal cancer patients].
    Liu XN; Tian Z; Wei XF; Wang Q; Zhang JX; Jin MS; Duan XM
    Zhonghua Bing Li Xue Za Zhi; 2019 May; 48(5):373-377. PubMed ID: 31104677
    [No Abstract]   [Full Text] [Related]  

  • 40. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.